title: Hyaluronectin secretion by monocytes: downregulation by IL-4 and IL-13, upregulation by IL-10.
abstract: Hyaluronectin (HN) is a component of the extracellular matrix of connective tissue and is particularly associated with tumour inflammatory and connective stroma reaction, where it co-localizes with hyaluronic acid (HA). The HN/HA ratio has been suggested to be involved in tumour aggressivity and in the atherosclerosis process. IL-10 has also been described in atherosclerotic lesions and in cancer. HN production was therefore investigated in vitro in peripheral blood monocyte cell (PBMC) cultures, with and without bacterial lipolysaccharide (LPS) or interleukins (ILs) in the medium. HN was characterized in monocytic cell cytoplasm and in culture supernatants. Anti-IL-10 antibody suppressed the LPS-stimulating effect on HN production. HN synthesis rate was greatly increased in IL-10-activated cultures while IL-4 and IL-13, two other anti-inflammatory ILs, decreased HN release. In the presence of IL-10, the IL-4 or Il-13 inhibitory effect on HN synthesis was reversed. The results support the view that intratumoral release of IL-10 by monocytes may induce local production of HN. In conjunction with the known ability of HN to bind to HA, which is a cell migration and tumour invasion facilitating factor, and to inhibit HA-induced angiogenesis, our findings suggest that HN may modulate the effect of HA on atherosclerosis, angiogenesis and cancer development.
authors.affiliation: Laboratoire d'oncologie moléculaire, Université de Rouen, Rouen, France. nicgir@rouen.fnclcc.fr
authors.forename: N
authors.initials: N
authors.lastname: Girard
authors.forename: C
authors.initials: C
authors.lastname: Maingonnat
authors.forename: P
authors.initials: P
authors.lastname: Bertrand
authors.forename: M
authors.initials: M
authors.lastname: Vasse
authors.forename: B
authors.initials: B
authors.lastname: Delpech
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D002352:Carrier Proteins / Q000032:analysis / Q000096:biosynthesis* / Q000378:metabolism; D002478:Cells, Cultured; D003593:Cytoplasm / Q000502:physiology; D006023:Glycoproteins / Q000032:analysis / Q000096:biosynthesis* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D016753:Interleukin-10 / Q000276:immunology / Q000494:pharmacology*; D018793:Interleukin-13 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects / Q000502:physiology*
chemical_list: D000906:Antibodies; D002352:Carrier Proteins; D006023:Glycoproteins; D018793:Interleukin-13; D008070:Lipopolysaccharides; C108676:hyaluronectin protein, human; D016753:Interleukin-10; D015847:Interleukin-4